Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. National Taiwan University Hospital / 醫學院附設醫院 (臺大醫院)
  4. Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma.
 
  • Details

Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma.

Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Start Page
CODEN JFASE
ISSN
0929-6646
Date Issued
2025-11-07
Author(s)
Chen, Ching-Tso
Feng, Yin-Hsun
Yen, Chia-Jui
Chen, San-Chi
Hsu, Chih-Hung
YU-YUN SHAO  
DOI
10.1016/j.jfma.2025.11.006
URI
https://scholars.lib.ntu.edu.tw/handle/123456789/735674
Abstract
Immunotherapy combinations, such as atezolizumab plus bevacizumab (Atezo-Bev) or durvalumab plus tremelimumab, have been established as standard treatments for patients with advanced hepatocellular carcinoma (HCC). Durable responses and long-term survival have been reported following dual immunotherapy. However, the long-term outcomes associated with Atezo-Bev treatment remain unclear.
To evaluate survival outcomes, we retrospectively analyzed medical records for patients with Child-Pugh class A liver function who received first-line Atezo-Bev for advanced HCC from January 2018 to May 2021 from four medical centers in Taiwan.
A total of 54 patients were included in the analysis. This cohort was predominantly male (90.7%) and had a median age of 65 years. After a median follow-up period of 61.9 months, the median overall survival (OS) was 19.6 months (95% confidence interval, 10.1-20.1 months). The OS rates at 36, 48, and 60 months were 31.6%, 19.6%, and 19.6%, respectively. Younger age (≤70 years), absence of intrahepatic tumors, absence of macrovascular invasion (MVI), and Albumin-Bilirubin (ALBI) grade 1 liver function were associated with long-term survival (>36 months). A multivariate analysis revealed the absence of intrahepatic tumors (odds ratio [OR] = 5.36, p = 0.047) and ALBI grade 1 (OR = 10.02, p = 0.037) as independent predictors of long-term survival. Among patients achieving complete or partial response, the 60-month OS rate was 47.4%.
Among patients with advanced HCC treated with first-line Atezo-Bev, approximately 30% survived beyond 3 years. The absence of intrahepatic tumors and preserved liver function were predictive of such prolonged survival.
Subjects
Immune checkpoint inhibitors
Liver cancer
Long-term survival
Prognosis
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science